All In Biotech

Drug Trial Radar · NCT07219043

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Feb 10, 2028

Study completion Feb 10, 2028

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI is a type of injury to small blood vessels in the transplanted kidney and may be a sign of rejection by the body. It can lead to serious kidney problems over time. In many cases, MVI is caused by antibodies that attack the transplanted kidney. But in some people, MVI happens without these antibodies. This type of MVI is called isolated MVI. There are currently no approved treatments for isolated MVI. The main goal of the study is to learn about the effect felzartamab has on inflammation in the transplanted kidney. The main question researchers want to answer is: • How many participants have no signs of active inflammation in the transplanted kidney after 24 weeks of treatment with felzartamab? Researchers will also study how felzartamab affects kidney function, immune activity, and overall health. They will monitor safety through kidney biopsies, lab tests, and by recording adverse events throughout the study. Adverse events are health problems that may or may not be caused by the study drug. The study will be done in 2 parts as follows: * Participants will be randomly assigned to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * In Part A, participants will receive their assigned drug for 24 weeks. Neither the researchers nor the participants will know who is receiving felzartamab or placebo. * Part B will last another 28 weeks. All participants will receive felzartamab and both participants and researchers will know this. * All treatments will be given by intravenous (IV) infusion at the study site. * Participants will have kidney biopsies at the start of the study, at Week 24, and at Week 52 to help measure changes in inflammation. * Participants will stay in the study for about 1 year.

Conditions

  • Microvascular Inflammation

Interventions

  • FelzartamabDrug

    Administered IV

  • PlaceboDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)Time frame: Week 24

Locations

53 sites in 11 countries. Site status is shown where the registry gives one.

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Keck Hispital of University of Southern California (USC)

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Providence St. Joseph Hospital Orange

    Orange, California · Recruiting

  • Sutter Health - California Pacific Medical Center

    San Francisco, California · Recruiting

  • University of California San Fransisco (UCSF) Medical Center

    San Francisco, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • The University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University of Michigan Medical Center

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Cooperman Barnabas Medical Center

    West Orange, New Jersey · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Penn Medicine - Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • Virginia Commonwealth University (VCU) Medical Center (Main Hospital) Hume-Lee Transplant Center

    Richmond, Virginia · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Clínica Privada Vélez Sarsfield

    Córdoba, Argentina · Recruiting

  • Instituto de Trasplante y Alta Complejidad (ITAC)

    Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • Hospital do Rim - Fundação Oswaldo Ramos

    São Paulo, Brazil · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)

    São Paulo, Brazil · Recruiting

  • Hospital de Base da Faculdade de Medicina de São José do Rio Preto

    Vila São José, São José Do Rio Preto, Brazil · Recruiting

  • Alberta Health Services (AHS) - University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Providence Health Care - St. Paul's Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Institut klinicke a experimentalni mediciny (IKEM)

    Prague, Czechia · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin

    Bordeaux, France · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.